Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor and has documented single-agent activity in patients with recurrent ovarian cancer. The current study demonstrated that when combined with standard recurrent chemotherapy, bevacizumab can significantly improve progression-free survival and objective response rate without diminishing quality of life.SOURCE:
Pujade-Lauraine E, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA openlabel randomized Phase III trial. J Clin Oncol 2014;32:1302-1308.